Xencor Inc (XNCR) Given Average Rating of “Buy” by Brokerages

Xencor Inc (NASDAQ:XNCR) has been assigned an average recommendation of “Buy” from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $41.87.

XNCR has been the topic of a number of research reports. Raymond James initiated coverage on Xencor in a research note on Thursday, March 14th. They set an “outperform” rating and a $27.85 price target on the stock. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, February 22nd. Piper Jaffray Companies upped their price target on Xencor to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price target on shares of Xencor in a research note on Tuesday, February 5th. Finally, Guggenheim initiated coverage on Xencor in a research note on Friday, April 12th. They set a “buy” rating and a $42.00 price target on the stock.

NASDAQ:XNCR traded down $3.16 during trading hours on Monday, reaching $32.48. 227,800 shares of the stock were exchanged, compared to its average volume of 218,471. Xencor has a twelve month low of $27.75 and a twelve month high of $48.38. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -24.79 and a beta of 1.35.



Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.95. The firm had revenue of $111.94 million for the quarter, compared to analyst estimates of $60.05 million. As a group, equities analysts predict that Xencor will post -0.84 earnings per share for the current fiscal year.

In related news, major shareholder John S. Stafford III acquired 14,611 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were acquired at an average price of $29.87 per share, with a total value of $436,430.57. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder John S. Stafford III acquired 38,300 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were bought at an average cost of $29.02 per share, for a total transaction of $1,111,466.00. The disclosure for this purchase can be found here. Insiders have bought 61,511 shares of company stock worth $1,804,827 in the last ninety days. Corporate insiders own 4.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of XNCR. Vanguard Group Inc increased its position in shares of Xencor by 33.0% during the third quarter. Vanguard Group Inc now owns 4,195,674 shares of the biopharmaceutical company’s stock worth $163,506,000 after acquiring an additional 1,040,578 shares during the period. Vanguard Group Inc. increased its holdings in Xencor by 33.0% in the third quarter. Vanguard Group Inc. now owns 4,195,674 shares of the biopharmaceutical company’s stock valued at $163,506,000 after buying an additional 1,040,578 shares during the last quarter. Norges Bank purchased a new position in Xencor in the fourth quarter valued at $28,271,000. Sofinnova Investments Inc. purchased a new position in Xencor in the fourth quarter valued at $7,221,000. Finally, Dimensional Fund Advisors LP increased its holdings in Xencor by 42.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 399,186 shares of the biopharmaceutical company’s stock valued at $14,432,000 after buying an additional 119,347 shares during the last quarter. 84.80% of the stock is currently owned by institutional investors and hedge funds.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Moving Average (MA)

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.